Sarepta Therapeutics (SRPT) Income from Continuing Operations (2010 - 2026)
Sarepta Therapeutics' (SRPT) quarterly Income from Continuing Operations came in at 330974000.0 in Q1 2026, up 173.96% year-on-year from 120812083.53 in Q1 2025, and up 217.0% quarter-over-quarter from 282881000.0 in Q4 2025.
Sarepta Therapeutics (SRPT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 330974000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 173.96% year-over-year to 330974000.0 in Q1 2026; TTM through Mar 2026 was 65084000.0, a 126.18% increase from a year earlier, with the FY2025 full-year figure at 713410000.0, down 403.59% from the prior year.
- Income from Continuing Operations improved to 330974000.0 in Q1 2026 per SRPT's latest filing, from 282881000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 330974000.0 in Q1 2026 and bottomed at 516710000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 23940000.0 (2023), against an average of 55791176.47.
- Biggest YoY gain for Income from Continuing Operations was 2948.58% in 2025; the steepest drop was 1339.01% in 2025.
- Year by year, Income from Continuing Operations stood at 329335000.0 in 2022, then slumped by 86.19% to 45490000.0 in 2023, then soared by 249.09% to 158800000.0 in 2024, then plunged by 278.14% to 282881000.0 in 2025, then jumped by 217.0% to 330974000.0 in 2026.
- Per Business Quant, the three latest SRPT Income from Continuing Operations figures stand at 330974000.0 (Q1 2026), 282881000.0 (Q4 2025), and 179947000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Sarepta Therapeutics | 1.66 Bn | 1.25 Bn | 622.04 Mn | 330.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 330.97 Mn |
| Dec 31, 2025 | -282.88 Mn |
| Sep 30, 2025 | -179.95 Mn |
| Jun 30, 2025 | 196.94 Mn |
| Mar 31, 2025 | -447.52 Mn |
| Dec 31, 2024 | 158.80 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 6.46 Mn |
| Mar 31, 2024 | 36.12 Mn |
| Dec 31, 2023 | 45.49 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -23.94 Mn |
| Mar 31, 2023 | -516.71 Mn |
| Dec 31, 2022 | 329.34 Mn |
| Sep 30, 2022 | -257.74 Mn |
| Jun 30, 2022 | -231.48 Mn |
| Mar 31, 2022 | -105.03 Mn |
| Dec 31, 2021 | -122.29 Mn |
| Sep 30, 2021 | -48.14 Mn |
| Jun 30, 2021 | -81.41 Mn |